NLS Pharmaceutics AG
NASDAQ:NLSP
Intrinsic Value
NLS Pharmaceutics Ltd. engages in the discovery and development of drug therapies to treat rare and complex central nervous systems disorders, including narcolepsy, idiopathic hypersomnia and other ra... [ Read More ]
The intrinsic value of one
NLSP
stock under the Base Case scenario is
0.2262
USD.
Compared to the current market price of 0.1367 USD,
NLS Pharmaceutics AG
is
Undervalued by 40%.
NLS Pharmaceutics AG's market capitalization is 5.4m USD.
NLSP stock price is 0.1367 USD.
NLSP stock price (0.1367 USD) is 40% less than its Intrinsic Value (0.2262 USD).
NLSP. Open Relative Valuation
NLSP.
NLSP has negative Free Cash Flow for the last twelve months.
NLSP has negative Operating Income for the last twelve months.
NLSP has negative Net Income for the last twelve months.
NLSP's ROE (Return on Equity) has significantly increased in the last 3 years from 38% to 371%.
NLSP's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from 94% to 709%.
NLSP's ROE (Return on Equity) for the past 12 months is very high and is equal to 371%.
NLSP's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 709%.
NLSP's short-term liabilties (4m USD) exceed its short-term assets (2m USD).
NLSP's long-term liabilties (7m USD) exceed its long-term assets (2m USD).
NLSP has negative three-year average ROE (Return on Equity): -2 113%. The company is not efficient at transforming stockholders' equity into net income.
NLSP has very high three-year average ROIC (Return on Invested Capital): 875%. The company is very efficient at using invested capital to generate operating income.
NLSP's D/E (Debt to Equity) is very low and is equal to 0.
NLSP's Altman Z-Score is very low and is equal to -60.55.
Valuation Backtest
NLS Pharmaceutics AG
Run backtest to discover the historical profit from buying and selling
NLSP
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
NLS Pharmaceutics AG
Balance Sheet Decomposition
NLS Pharmaceutics AG
| Current Assets | 2.2m |
| Cash & Short-Term Investments | 1.7m |
| Receivables | 64.3k |
| Other Current Assets | 529.5k |
| Non-Current Assets | 25k |
| PP&E | 12.4k |
| Other Non-Current Assets | 12.6k |
| Current Liabilities | 3.9m |
| Accounts Payable | 3.1m |
| Accrued Liabilities | 779.4k |
| Other Current Liabilities | -10 |
| Non-Current Liabilities | 2.7m |
| Other Non-Current Liabilities | 2.7m |
Earnings Waterfall
NLS Pharmaceutics AG
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-15.3m
USD
|
|
Operating Income
|
-15.3m
USD
|
|
Other Expenses
|
-193.3k
USD
|
|
Net Income
|
-15.5m
USD
|
Free Cash Flow Analysis
NLS Pharmaceutics AG
NLSP Profitability Score
Profitability Due Diligence
NLS Pharmaceutics AG's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
NLS Pharmaceutics AG's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
NLSP Solvency Score
Solvency Due Diligence
NLS Pharmaceutics AG's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Score
NLS Pharmaceutics AG's solvency score is 39/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
NLSP Price Targets Summary
NLS Pharmaceutics AG
Shareholder Return
NLSP Price
NLS Pharmaceutics AG
| Average Annual Return | -20.59% |
| Standard Deviation of Annual Returns | 54.07% |
| Max Drawdown | -98% |
| Market Capitalization | 5.4m USD |
| Shares Outstanding | 39 560 000 |
| Percentage of Shares Shorted | 1.33% |
Company Profile
NLS Pharmaceutics AG
Country
Industry
Market Cap
Dividend Yield
Description
NLS Pharmaceutics Ltd. engages in the discovery and development of drug therapies to treat rare and complex central nervous systems disorders, including narcolepsy, idiopathic hypersomnia and other rare sleep disorders, and of neurodevelopmental disorders, such as Attention Deficit Hyperactivity Disorder. The company is headquartered in Stans, Nidwalden and currently employs 6 full-time employees. The firm focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The firm serves customers worldwide.
Officers
The intrinsic value of one
NLSP
stock under the Base Case scenario is
0.2262
USD.
Compared to the current market price of 0.1367 USD,
NLS Pharmaceutics AG
is
Undervalued by 40%.
You don't have any saved screeners yet
